PURPOSE: Multi-centre trials are an important part of proving the efficacy of procedures, drugs and interventions. Imaging components in such trials are becoming increasingly common; however, without sufficient control measures the usefulness of these data can be compromised. This paper describes a framework for performing high-quality multi-centre trials with single photon emission computed tomography (SPECT), using a pan-European initiative to acquire a normal control dopamine transporter brain scan database as an example. METHODS: A framework to produce high-quality and consistent SPECT imaging data was based on three key areas: quality assurance, the imaging protocol and system characterisation. Quality assurance was important to ensure that the quality of the equipment and local techniques was good and consistently high; system characterisation helped understand and where possible match the performance of the systems involved, whereas the imaging protocol was designed to allow a degree of flexibility to best match the characteristics of each imaging device. RESULTS: A total of 24 cameras on 15 sites from 8 different manufacturers were evaluated for inclusion in our multi-centre initiative. All results matched the required level of specification and each had their performance characterised. Differences in performance were found between different system types and cameras of the same type. Imaging protocols for each site were modified to match their individual characteristics to produce comparable high-quality SPECT images. CONCLUSION: A framework has been designed to produce high-quality data for multi-centre SPECT studies. This framework has been successfully applied to a pan-European initiative to acquire a healthy control dopamine transporter image database.
PURPOSE: Multi-centre trials are an important part of proving the efficacy of procedures, drugs and interventions. Imaging components in such trials are becoming increasingly common; however, without sufficient control measures the usefulness of these data can be compromised. This paper describes a framework for performing high-quality multi-centre trials with single photon emission computed tomography (SPECT), using a pan-European initiative to acquire a normal control dopamine transporter brain scan database as an example. METHODS: A framework to produce high-quality and consistent SPECT imaging data was based on three key areas: quality assurance, the imaging protocol and system characterisation. Quality assurance was important to ensure that the quality of the equipment and local techniques was good and consistently high; system characterisation helped understand and where possible match the performance of the systems involved, whereas the imaging protocol was designed to allow a degree of flexibility to best match the characteristics of each imaging device. RESULTS: A total of 24 cameras on 15 sites from 8 different manufacturers were evaluated for inclusion in our multi-centre initiative. All results matched the required level of specification and each had their performance characterised. Differences in performance were found between different system types and cameras of the same type. Imaging protocols for each site were modified to match their individual characteristics to produce comparable high-quality SPECT images. CONCLUSION: A framework has been designed to produce high-quality data for multi-centre SPECT studies. This framework has been successfully applied to a pan-European initiative to acquire a healthy control dopamine transporter image database.
Authors: Ronald Boellaard; Wim J G Oyen; Corneline J Hoekstra; Otto S Hoekstra; Eric P Visser; Antoon T Willemsen; Bertjan Arends; Fred J Verzijlbergen; Josee Zijlstra; Anne M Paans; Emile F I Comans; Jan Pruim Journal: Eur J Nucl Med Mol Imaging Date: 2008-08-15 Impact factor: 9.236
Authors: Boon-Keng Teo; Youngho Seo; Stephen L Bacharach; Jorge A Carrasquillo; Steven K Libutti; Himanshu Shukla; Bruce H Hasegawa; Randall A Hawkins; Benjamin L Franc Journal: J Nucl Med Date: 2007-05 Impact factor: 10.057
Authors: Dan J Kadrmas; Michael E Casey; Maurizio Conti; Bjoern W Jakoby; Cristina Lois; David W Townsend Journal: J Nucl Med Date: 2009-07-17 Impact factor: 10.057
Authors: Jenny McCleery; Shirlony Morgan; Kevin M Bradley; Anna H Noel-Storr; Olaf Ansorge; Chris Hyde Journal: Cochrane Database Syst Rev Date: 2015-01-30
Authors: Andrea Varrone; John C Dickson; Livia Tossici-Bolt; Terez Sera; Susanne Asenbaum; Jan Booij; Ozlem L Kapucu; Andreas Kluge; Gitte M Knudsen; Pierre Malick Koulibaly; Flavio Nobili; Marco Pagani; Osama Sabri; Thierry Vander Borght; Koen Van Laere; Klaus Tatsch Journal: Eur J Nucl Med Mol Imaging Date: 2012-11-16 Impact factor: 9.236
Authors: Walter Koch; Marcus Unterrainer; Guoming Xiong; Peter Bartenstein; Markus Diemling; Andrea Varrone; John C Dickson; Livia Tossici-Bolt; Terez Sera; Susanne Asenbaum; Jan Booij; Ozlem L Kapucu; Andreas Kluge; Morten Ziebell; Jacques Darcourt; Flavio Nobili; Marco Pagani; Swen Hesse; Thierry Vander Borght; Koen Van Laere; Klaus Tatsch; Christian la Fougère Journal: Eur J Nucl Med Mol Imaging Date: 2014-05-08 Impact factor: 9.236
Authors: Nicolas Nicastro; Valentina Garibotto; Antoine Poncet; Simon Badoud; Pierre R Burkhard Journal: Mol Imaging Biol Date: 2016-04 Impact factor: 3.488
Authors: Gerda Thomsen; Gitte Moos Knudsen; Peter S Jensen; Morten Ziebell; Klaus K Holst; Susanne Asenbaum; Jan Booij; Jacques Darcourt; John C Dickson; Ozlem L Kapucu; Flavio Nobili; Osama Sabri; Terez Sera; Klaus Tatsch; Livia Tossici-Bolt; Koen Van Laere; Thierry Vander Borght; Andrea Varrone; Marco Pagani; Lars Hageman Pinborg Journal: EJNMMI Res Date: 2013-05-20 Impact factor: 3.138